AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

Vysis, Inc., a leading genomic disease management ... Abbott created the Established Pharmaceuticals Division in 2010. The creation of AbbVie In 2011, Abbott announced it was to separate into ...

Tarsus Pharmaceuticals is expanding its pipeline to target meibomian gland disease and rosacea, with promising Phase 2 ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

New, more expensive migraine drugs are no more effective against the throbbing headaches than traditional painkillers, and ...

KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access ...

That said, investors who do their research can sometimes find durable growth stories that will last for many years to come. Stocks that have strong share price momentum coupled with consistent growth ...

Rayne Beau, a lost cat, managed to travel 800 miles back home after vanishing during a camping trip in Yellowstone National Park. Found exhausted in Roseville, California, he was reunited with his ...

A shortlist of the biggest headlines, recommended stories, and a special collection of news items that you should check out.

Greece is to battle the housing crisis by further regulating Airbnb and house rentals as of 2025, imposing restrictions on short-term leasing while providing incentives for long-term rentals to owners ...